- Intermediate compound of parecoxib sodium
-
The invention belongs to the technical field of medicines, and provides an intermediate compound of parecoxib sodium and parecoxib synthesized by using the intermediate compound. The use of chlorosulfonic acid is avoided, and meanwhile, the generation of related genotoxic impurities, isomer impurities, dimer impurities and the like introduced by the use of chlorosulfonic acid is avoided. The product obtained through the preparation process is high in yield and purity, and the technical method is low in production cost, high in safety, small in pollution and suitable for industrial production of parecoxib sodium.
- -
-
-
- Parecoxib sodium intermediate compound
-
The invention belongs to the technical field of drug synthesis, and provides a parecoxib intermediate and a method for synthesizing parecoxib by using the parecoxib intermediate, so that the use of chlorosulfonic acid is avoided, and meanwhile, the generation of related genotoxic impurities, isomer impurities, dimer impurities and the like introduced by the use of chlorosulfonic acid is avoided. The product obtained through the preparation process is high in yield and purity, and the technical method is low in production cost, high in safety, small in pollution and suitable for industrial production of parecoxib sodium.
- -
-
-
- Preparation method of parecoxib sodium
-
The invention belongs to the technical field of medicines, and particularly relates to a preparation method of parecoxib sodium. 5-methyl-3, 4-diphenyl isoxazole is used as a raw material, and the parecoxib sodium is obtained through sulfonation reaction, ammoniation reaction, propionylation reaction and salification. The method has the advantages of mild reaction, easy operation, great reductionof the generation of HCl gas, short reaction time, high product yield, and suitableness for industrial production.
- -
-
-
- Parecoxib sodium, injection preparation and preparation method
-
The invention discloses parecoxib sodium, an injection preparation and a preparation method. The preparation method of the parecoxib sodium is as follows: 5-methyl-3,4-diphenylisoxazole is used as theraw material; sulfonation and amination are carried out in sequence, so that a valdecoxib intermediate is obtained; then, the valdecoxib intermediate is subjected to acylation reaction and salt forming reaction, so that crude parecoxib sodium is obtained; the crude parecoxib sodium is dissolved and decolourized, so that the finished parecoxib sodium is obtained; the finished parecoxib sodium is the parecoxib sodium A crystal form; and the parecoxib sodium preparation for injection is prepared by adding accessories into the parecoxib sodium A crystal form. The preparation method of the parecoxib sodium in the invention is simple in synthetic route and moderate in reaction condition; raw materials are available at low prices; and furthermore, the impurity content of the prepared parecoxib sodium is low.
- -
-
-
- Preparation method of parecoxib sodium
-
The invention belongs to the technical field of drug preparation, and specifically relates to a preparation method of parecoxib sodium. The preparation method comprises sulfonation reactions, amination reactions, propionylation reactions, and salt forming reactions. In sulfonation reactions, 5-methyl-3,4-diphenyl isoxazole is taken as the primary raw material and directly carries out reactions with chlorosulfonic acid, after reactions, and the reaction system is poured into water to carry out quenching to obtain suspension of reaction products. All used reagents are common reagents; the preparation method only uses third kind solvents, which are regulated by International Council for Harmonization (ICH) and are harmless for human body; the operation of the preparation method and post treatment is simple, the repeatability is good, the yield is high, and the cost is low. The purity of prepared parecoxib sodium can reach 99.9% or more. The quality of prepared parecoxib sodium is higher than the standards made by a plant that develops parecoxib sodium. The preparation method is suitable for industrial production of pharmaceutical enterprises.
- -
-
-
- A handkerchief auspicious past cloth sodium freeze-dried powder, its preparation method and its powder products
-
The invention discloses a parecoxib sodium freeze-dried powder, a preparation method and a powder product thereof. The freeze-dried powder comprises 95-100 wt% of the parecoxib sodium and 0-5 wt% of a pH regulator; or 40-100 wt% of the parecoxib sodium and 0-60 wt% of L-malate. The freeze-dried powder has simple preparation method, is free of auxiliary materials or employs few auxiliary materials, is reduced in cost, and satisfies national medicine standards in storage stability, clinical application stability and safety.
- -
-
-
- Rhodium(iii)-catalyzed sulfonamide directed ortho C-H carbenoid functionalization via metal carbene migratory insertion
-
A rhodium(iii)-catalyzed sulfonamide directed ortho C-H carbenoid functionalization has been developed with good yields. This method is attractive due to its broad substrate scope, and enables derivation of diverse biologically active sulfonamide structures and late-stage modification of sulfa drugs.
- Dong, Yi,Chen, Jiajing,Xu, Heng
-
supporting information
p. 2027 - 2030
(2019/02/19)
-
- A synthesis method of intermediate handkerchief auspicious past cloth handkerchief auspicious past cloth sodium (by machine translation)
-
The invention provides a method for synthesis of intermediate handkerchief auspicious past cloth sodium handkerchief auspicious past cloth, the use of the synthesis handkerchief auspicious past cloth obtained by the method of high yield, high purity. The invention handkerchief auspicious past cloth synthetic method overcomes the problems of the prior art production yield is low, the production cost is high. More conducive to the industrial production of the handkerchief auspicious past cloth. (by machine translation)
- -
-
Paragraph 0027; 0033-0047
(2019/10/17)
-
- A process for the preparation of the handkerchief auspicious past cloth method
-
The invention discloses a method for preparing parecoxib. The method comprises the following steps: an initial raw material 3-oxo-2-phenylbutanoyl chloride and benzene undergo a Friedel-Crafts reaction to generate 1,2-diphenylbutane-1,3-dione, 1,2-diphenylbutane-1,3-dione is sulfonated by chlorosulfonic acid or concentrated sulfuric acid/acetyl chloride to obtain 4-(1,3-dioxo-1-phenylbutyl-2-yl)-1-sulfonyl chloride, 4-(1,3-dioxo-1-phenylbutyl-2-yl)-1-sulfonyl chloride is acted by ammonia water to generate 4-(1,3-dioxo-1-phenylbutyl-2-yl)-1-sulfonamide, and 4-(1,3-dioxo-1-phenylbutyl-2-yl)-1-sulfonamide reacts with propionic anhydride or propionyl chloride to obtain N-(4-(1,3-dioxo-1-phenylbutyl-2-yl)phenylsulfonyl)propionamide, N-(4-(1,3-dioxo-1-phenylbutyl-2-yl)phenylsulfonyl)propionamide undergoes condensation by using hydroxylamine hydrochloride to synthesize a ring, and dehydration is carried out under an acidic condition to obtain parecoxib. The parecoxib is prepared from 3-oxo-2-phenylbutanoyl chloride as the initial raw material through the Friedel-Crafts reaction, a sulfonation reaction, an amidation reaction and a condensation reaction. The method has the advantages of low cost of the initial raw material, simple process, low requirements of reaction conditions, simple post-treatment operation, high product yield and purity, and realization of large-scale production.
- -
-
-
- Bone-targeted parecoxib sodium nanocapsule freeze-dried injection and preparation method thereof
-
The invention discloses a bone-targeted nanocapsule freeze-dried injection containing parecoxib sodium and a preparation method of the injection. By virtue of a preparation, namely the injection, the concentration of parecoxib sodium in a bone tissue can be increased, so that the effects of parecoxib sodium in orthopedic surgeries and bone cancer analgesia are improved. By utilizing a capsule material and a carrier material which have good biodegradability and biocompatibility, a drug can be tightly combined with soft and hard tissues in a human body in a short time after entering the human body so as to rapidly play a role of treatment. By utilizing a nanocapsule packaging manner, the content of degradation products of the preparation is extremely low.
- -
-
-
- Preparation methods of parecoxib sodium and intermediate thereof
-
The invention discloses preparation methods of parecoxib sodium and intermediate thereof. The invention provides a preparation method of a parecoxib sodium intermediate I. The preparation method of the parecoxib sodium intermediate I comprises the following step: in the presence of a catalyst, performing condensation reaction on valdecoxib III and propionic anhydride to obtain the parecoxib sodium intermediate I, wherein the catalyst is one or more of benzenesulfonic acid, p-toluenesulfonic acid, methanesulfonic acid and sulfamic acid. The preparation method is simple in reaction and post-treating operation, high in yield and low in cost; the purity of the prepared intermediate product is high and can reach 99.80% or above, and the content of specific impurity valdecoxib reaches 0.02% or below and can meet the standard of an original researching manufacturer; therefore, the preparation method is suitable for industrial production. The purity of parecoxib sodium prepared from the parecoxib sodium intermediate I prepared by the preparation method provided by the invention can reach 99.80% or above and the content of the specific impurity valdecoxib reaches 0.01% or below and is higher than the standard of the original researching manufacturer.
- -
-
Paragraph 0038-0048
(2017/08/29)
-
- A method of preparing intermediates handkerchief auspicious past cloth sodium
-
The invention discloses a novel method for preparing a parecoxib sodium intermediate 5-methyl-3, 4-diphenyl isoxazole. The method comprises the following steps: performing rearrangement reaction on a compound in the formula I (referring to the Specification)under the action of a catalyst to prepare a compound in the formula II(referring to the Specification); and under the condition of a catalyst, reacting hydroxylammonium chloride with the compound in the formula II to prepare 5-methyl-3,4-diphenyl isoxazole. The method disclosed by the invention has the advantages of mild reaction condition, good simplicity and convenience for operation, low cost, environmental-friendliness and the like.
- -
-
-
- A process for the preparation of sodium compound handkerchief auspicious past cloth and wherein the intermediate impurity, preparation method and application
-
The invention provides parecoxib sodium which is prepared by controlling an intermediate impurity and in particular provides a preparation method of a parecoxib sodium compound as well as the intermediate impurity and an application of the parecoxib sodium compound. According to the preparation method provided by the invention, 3-methyl-4,5-diphenyl-4,5-dihydro-isoxazole-5-alcohol is used as an isomer impurity for preparing 5-methyl-3,4-diphenyl-4,5-dihydro-isoxazole-5-alcohol as an intermediate of the parecoxib sodium, the quality of the 3-methyl-4,5-diphenyl-4,5-dihydro-isoxazole-5-alcohol is controlled in the preparation of the parecoxib sodium, specifically, the impurity content is required not to be higher than 0.5 percent, and an important significance is provided for the product quality of the parecoxib sodium; by obtaining the 3-methyl-4,5-diphenyl-4,5-dihydro-isoxazole-5-alcohol as an isomer impurity of the important 5-methyl-3,4-diphenyl-4,5-dihydro-isoxazole-5-alcohol and further studying 3-methyl-4,5-diphenyl-4,5-dihydro-isoxazole-5-alcohol in the aspects of preparation process, detection process and purification process, important quality monitoring significance is provided for the process with the 5-methyl-3,4-diphenyl-4,5-dihydro-isoxazole-5-alcohol as an industrial production raw material.
- -
-
-
- Method for preparing parecoxib for treating postoperative pain
-
The invention discloses a method for preparing parecoxib for treating postoperative pain. The method comprises the following steps: 1) conducting a contact reaction between 3,4-diphenyl-4-(1-pyrrolidyl)-3-butene-2-one and ammonium acetate in acetic acid; after the reaction, diluting dichloromethane; regulating the pH value to 6-7 with saturated sodium bicarbonate; concentrating the organic phase and washing; recrystallizing with ethanol; and drying to obtain 5-methyl-3,4-diphenyl isoxazole; 2) stirring the obtained 5-methyl-3,4-diphenyl isoxazole and chlorosulfonic acid for reacting; adding anion exchange resin, and dropwise adding saturated ammonium chloride and dichloromethane for extraction; washing and concentrating; and recrystallizing with ethanol to obtain valdecoxib; and 3) enabling the valdecoxib obtained in the step 2) to react with propionic anhydride in the presence of triethylamine to obtain parecoxib. The method for preparing parecoxib, disclosed by the invention, has the advantages of simple steps, mild conditions and high yield.
- -
-
-
- Method for preparing cyclooxygenase-2 inhibitor parecoxib
-
The invention discloses a method for preparing a cyclooxygenase-2 inhibitor parecoxib. The method comprises the following steps: 1) enabling benzaldoxime and 1-(4-sulfonyl phenyl)propyne to react in an illumination condition in the presence of tri(2-phenylpyridine)iridium (III), triethylamine and magnesium oxide to obtain 5-methyl-3-phenyl-4-(4-sulfonyl phenyl)isoxazole; 2) conducting a contact reaction between 5-methyl-3-phenyl-4-(4-sulfonyl phenyl)isoxazole obtained in the step 1) and thionyl chloride; after the reaction, extracting dichloromethane; directly adding the dichloromethane phase into ammonia water; separating organic phase; washing and concentrating; and recrystallizing with ethanol to obtain valdecoxib; and 3) enabling the valdecoxib obtained in the step 2) to react with propionic anhydride in the presence of triethylamine to obtain parecoxib. The parecoxib preparation method disclosed by the invention has the advantages of simple steps, high yield and simple aftertreatment.
- -
-
-
- Method for preparing Parecoxib
-
The invention relates to a method for preparing Parecoxib, and belongs to the synthesis field of pharmaceutical chemistry. 1,2-diphenyl-ethanone is used as an starting raw material, a reaction is carried out between the starting raw material and chlorosul
- -
-
-
- Preparation method of cyclooxygenase-2 inhibitor parecoxib
-
The invention discloses a preparation method of a cyclooxygenase-2 inhibitor parecoxib. The method comprises the following steps that 1, benzaldoxime reacts with 1-phenylpropyne in the presence of tris(2-phenylpyridine)iridium (III), triethylamine and magnesium oxide under the illumination condition to obtain 5-methyl-3,4-diphenylisoxazole; 2, a stirring reaction is conducted on 5-methyl-3,4-diphenylisoxazole obtained in the first step and chlorosulfonic acid, dichloromethane extraction is conducted after the reaction is completed, a dichloromethane phase is directly added into ammonium hydroxide, an organic phase is separated, water washing, concentrating and ethanol recrystallization are conducted, and valdecoxib is obtained; 3, valdecoxib obtained in the second step reacts with propionic anhydride in the presence of triethylamine, and parecoxib is obtained. The preparation method of parecoxib is simple in step, high in yield and simple in posttreatment.
- -
-
-
- METHOD FOR THE PREPARATION OF DIARYLISOXAZOLE SULFONAMIDE COMPOUNDS AND INTERMEDIATES
-
The disclosure provides a method for the preparation of a diarylisoxazolé sulfonamide compound comprising contacting a deoxybenzoin with a secondary amine to form a diarylenamine compound; contacting the diarylenamine compound with an acetylating agent to form an acetyl diarylenamine compound; contacting the acetyl diarylenamine compound with a source of hydroxylamine to form an diaryl isoxazolol compound; eliminating water from the diaryl isoxazolol compound to form a diaryl isoxazole compound, chlorosulfonating the diarylisoxazole compound to form a chlorosulfonyl diaryl isoxazole compound; and contacting the chlorosulfonyl diaryl isoxazole compound with a source of ammonia to form the diarylisoxazole sulfonamide compound.
- -
-
Page/Page column 39
(2008/06/13)
-
- Method for preparing 3,4-diphenyl-substituted isoxazole compounds
-
The present invention relates to a process for preparing diaryl-substituted isoxazole using compounds of Formula (V) and Formula (VII): where Y is and to processes for preparing valdecoxib and parecoxib.
- -
-
Page/Page column 9
(2008/06/13)
-
- Method for preparing benzenesulfonyl compounds
-
The present disclosure provides a method for the preparation of aromatic sulfonyl halides by contacting a substituted phenyl compound with a halosulfonic acid and trifluoroacetic acid. The present disclosure further provides a method for the preparation of 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide which is useful in treating cyclooxygenase-2 related disorders.
- -
-
-
- Agents and methods for treatment of cancer
-
Agents and methods for chemoprevention and treatment of neoplasia are described, the agents including a selective inhibitor of inducible nitric oxide synthase and a combination of a selective inhibitor of inducible nitric oxide synthase and an inhibitor of cylcooxygenase-2 in a pharmaceutical composition. The agents and methods are used for chemoprevention and treatment of neoplasia including colorectal cancer and other cancers affecting epithelial cells throughout the body. The agents can also be used to treat the fibrosis that occurs with radiation therapy, as well as adenomatous polyps, including those with familial adenomatous polyposis (FAP).
- -
-
-
- THERAPEUTIC COMBINATIONS FOR CARDIOVASCULAR AND INFLAMMATORY INDICATIONS
-
The present invention provides therapeutic combinations and methods for treating or preventing a hypercholesterolemia-related or an inflammation-related condition in a subject in need of such treatment or prevention. One therapeutic combination comprises
- -
-
-
- Method for the treatment and prevention of cachexia
-
Cachexia, including anorexia and other forms of weight loss, is a frequent complication of acute and chronic infections, and result from induction of cytokines, prostaglandins, and other inflammatory mediators that are critical for pathogen elimination. The present invention includes methods for the treatment or prevention of cachexic conditions while maintaining the production of factors essential for infection control through the administration of an effective amount of a cyclooxygenase-2 selective inhibiting compound.
- -
-
-
- Crystalline parecoxib sodium
-
Parecoxib sodium is provided in a crystalline form that is substantially anhydrous and substantially nonsolvated. Various such anhydrous, nonsolvated crystal forms have been identified, including Forms A, B and E as described herein. Also provided is a parecoxib sodium drug substance wherein at least about 90% of the parecoxib sodium is in one or more anhydrous, nonsolvated crystal forms. Such a drug substance is a storage-stable intermediate that can be further processed, for example by dissolution or slurrying in an aqueous medium together with one or more parenterally acceptable excipients, followed by lyophilization of the resulting solution or slurry to provide a reconstitutable injectable composition suitable for therapeutic use.
- -
-
-
- Combination therapy using COX-2 selective inhibitor and thromboxane inhibitor and compositions therefor
-
The present invention provides a method for the treatment or prophylaxis of COX-2-mediated conditions in patients who are at risk of developing thromboembolic events which comprises administering to said patient a therapeutically or prophylactically effective amount of a COX-2 selective inhibitor and a cardiovascular protective amount of a thromboxane inhibitor, as well as compositions therefor.
- -
-
-
- Antiangiogenic combination therapy for the treatment of cancer
-
The present invention provides combinations of a DNA topoisomerase I inhibiting agent and a selective COX-2 inhibiting agent for preventing, treating, and/or reducing the risk of developing a neoplasia disorder in a mammal.
- -
-
-
- Use of selective COX-2 inhibitors for the treatment of urinary incontinence
-
The treatment of neuromuscular dysfunction of the lower urinary tract by compounds which selectively inhibit the COX-2 isozyme is described. The compounds concerned inhibit the COX-2 isozyme with a potency at least 10-fold, and preferably at least 100-fold, greater than their potency on the COX-1 isozyme.
- -
-
-
- Prodrugs of benzenesulfonamide-containing COX-2 inhibitors
-
Prodrugs of COX-2 inhibitors are described as being useful in treating inflammation and inflammation-related disorders.
- -
-
-
